admin

The kind of opportunity that technology and energy markets once offered is beckoning investors to property near biotech clusters. Emerging from the recession, technology and energy markets commanded the attention of commercial real-estate investors that wanted to tap into improving occupancy and rental rates largely absent elsewhere.

A similar dynamic is germinating in biotech clusters, which are typically marked by a high concentration of life-science companies near academic research institutions.

Trade-Ideas LLC identified Sucampo Pharmaceuticals ( SCMP) as a “dead cat bounce” (down big yesterday but up big today) candidate. In addition to specific proprietary factors, Trade-Ideas identified Sucampo Pharmaceuticals as such a stock due to the following factors:

Join us Nov. 19 for the 16th annual Bioscience Day at the University of Maryland, where we’ll explore “Systems Biology: Advancing Life Sciences and Medicine.”

Registration is free and lunch is provided.

Johns Hopkins researchers on Thursday unveiled a new medical research app that could help them better detect and manage epileptic seizures. The free app, called EpiWatch, is designed for the Apple Watch and iPhones. The app will collect data from patients before, during and after a seizure. Researchers are hopeful that after collecting data for one or two years, they will be able to develop an app that can detect most seizure types and generate an alert to call for help, if needed.

Malvern, Pennsylvania-based Galera Therapeutics, a biotech company focused on treating cancer patients, has closed $37 million in Series B funding. Novo Ventures led the round with participation from previous backers New Enterprise Associates, Novartis Venture Fund, Correlation Ventures and Galera Angels. In conjunction with the funding, Dr. Thomas Dyrberg, a managing partner of Novo Ventures, has been added to Galera’s board of directors.

People can lose their hearing for a variety of reasons, from age to loud noises, but there’s one thing they all have in common. There are no drugs to help them. Several companies have formed in recent years to address this gap, and now there’s another coming to the party a bit late, but with deep pockets—a new startup called Decibel Therapeutics, which is embarking on a broad effort to figure out what makes us go deaf in the first place.

Brian Stansky is the new director of Johns Hopkins’ incubator program for startups, according to a letter sent to colleagues from Christy Wyskiel, senior advisor to the president of Johns Hopkins on entrepreneurship and tech transfer. Nina Urban was appointed as associate director of the program.

Stansky served as interim director of the program for the last two months. He previously worked for 13 years as managing director at Integral Capital Partners, and oversaw health, sciences and media/telecom portfolios at T. Rowe Price.

Join REDI on October 22nd from 8:00-10:00am for the second edition of the Commercial Broker Breakfast (CBB). The CBB event combines networking and a mini trade show that includes local architects, bankers, contractors, interior designers, and other related vendors.

This year’s event is highlighted by a discussion with Benjamin Wu, Deputy Secretary for the Maryland Department of Commerce.

AstraZeneca’s ($AZN) MedImmune is joining the likes of Vanderbilt University and GlaxoSmithKline ($GSK) as a member of the Human Vaccines Project, the company announced Tuesday.

The public-private partnership, incubated at the International AIDS Vaccine Initiative (IAVI), aims to accelerate the development of vaccines and immunotherapies against major infectious diseases and cancers “by decoding the human immune system.”

Resveratrol for the win: Red wine drinkers had better levels of HDL cholesterol, better sleep and lower cardiometabolic risk factors

Why Two Minutes of Lost Footage From ‘The Civil War’ Documentary… Promoted Why You Should Be Getting Your Wine Online Recommended by Alcohol is the Goldilocks of the nutrition world. Too much can be destructive to your health, raising your blood pressure and your risk of developing several kinds of cancer. Too little may hold you back from some of the benefits that moderate drinkers enjoy, like lower incidence of cardiovascular disease, mortality and type-2 diabetes.